Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
John Maraganore is Director at City Therapeutics. OQRO lists 6 transactions filed with the SEC under this name, the latest on Oct 22, 2026, each linked to the official Form 4.
Director
Disclosures on record
6
Companies involved
2
John Maraganore bought shares on the open market in 2011, 2012, 2013, 2014, 2015 and 2026 across 3 companies. Sales in 13 of the 21 years since 2006.
John Maraganore reported 12 open-market purchases and 318 sales since 2006; purchases in 6 different years, most recently 2026.
| Year | Bought | Sold |
|---|---|---|
| 2026 | $249K2×2 trades | — |
| 2021 | — | $22.1M28×28 trades |
| 2020 | — | $18.6M16×16 trades |
| 2019 | — | $7.39M4×4 trades |
| 2018 | — | $7.27M9×9 trades |
| 2017 | — | $19M10×10 trades |
| 2016 | — | $6.15M27×27 trades |
| 2015 | $950K1×1 trade | $12.2M8×8 trades |
| 2014 | $400K3×3 trades | $22.7M16×16 trades |
| 2013 | $150K1×1 trade | $9.81M8×8 trades |
| 2012 | $70K2×2 trades | — |
| 2011 | $30K3×3 trades | — |
| 2009 | — | $2.57M5×5 trades |
| 2008 | — | $2.56M2×2 trades |
| 2007 | — | $1.18M120×120 trades |
| 2006 | — | $1.28M65×65 trades |
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
1 purchase disclosed. $1,000 placed after each of the 1 purchases disclosed since 2025-11-14 would be worth $1K today ($1K put in); the same in the S&P 500 (SPY): $993.
Not ranked: fewer than 10 purchases measured at 90 days. The middle of the 82 ranked insiders is −5.5 pts (median, against the S&P 500).
Equal weight counts every purchase once; by size counts it for its disclosed dollars. Both are measured from the first close after it was reported. Past results describe the past, not a forecast. How this is measured · Leaderboard
Rapport TherapeuticsRAPP
2 disclosures · Oct 2026 · 2 bought
Oct 22, 2026Bought~$217K
DetailsOfficial recordOct 22, 2026Bought~$32K
DetailsOfficial recordCity TherapeuticsCTY
4 disclosures · Oct 2026
Oct 15, 202623Kdisclosed Oct 20
DetailsOfficial recordOct 19, 2026611Kdisclosed Oct 20
DetailsOfficial recordOct 19, 2026500Kdisclosed Oct 20
DetailsOfficial recordOct 19, 202656Kdisclosed Oct 20
DetailsOfficial recordAs of the latest filing on , John Maraganore reported holding 1,470,692 shares of City Therapeutics (CTY), worth about $26.6M at the last close of $18 (Nov 13, 2026). Holdings are also on file at Rapport Therapeutics (RAPP), Takeda Pharmaceutical (TAK); together they are worth about $27.1M. In the last 12 months, John Maraganore bought $249K in 2 open-market purchases.
| Company | Shares reported | How held | Last close | Value at last close | Reported |
|---|---|---|---|---|---|
| City Therapeutics CTY | 1,470,692 | 1.47M direct | $18 | $26.6M | Oct 19, 2026 |
| Rapport Therapeutics RAPP | 9,411 | 9,411 john m. maraganore revocable trust | $26 | $246K | Oct 22, 2026 |
On the latest SEC Form 4, dated Oct 19, 2026, John Maraganore reported holding 1,470,692 shares of City Therapeutics (CTY). At the last close of $18 on Nov 13, 2026, that is about $26.6M. This is the stake disclosed in filings, not a net worth.
In SEC filings of the last 12 months, John Maraganore reported 2 open-market purchases worth $249K, and no open-market sale. Shares withheld for taxes, gifts and option exercises are not counted in these totals.
| Takeda Pharmaceutical TAK | 10,400 | 10K direct | $21 | $223K | Jul 1, 2026 |
Is this John Maraganore’s net worth? No. A Form 4 reports the shares an insider owns in one company after each transaction, directly or through trusts and entities. It says nothing about cash, other investments, property or debt, options not yet exercised are not counted here, and a holding reported some time ago may have changed without a new filing. The value is shares times the last stored close, not a price anyone received. Sources: the filings listed below, each linked to EDGAR. Compare with the biggest insider stakes.
John Maraganore bought shares on the open market in 2011, 2012, 2013, 2014, 2015 and 2026 across 3 companies. Sales in 13 of the 21 years since 2006.
In SEC filings since 2006: the latest open-market purchase is from 2026; the latest open-market sale is from 2021.
3 companies: Rapport Therapeutics (RAPP, 2026), Alnylam Pharmaceuticals (ALNY, 2006–2021), Agios Pharmaceuticals (AGIO, 2013–2018).
John Maraganore reported 6 open-market purchases and 314 sales here, 2006 to 2021.
John Maraganore reported 4 open-market purchases and 4 sales here, 2013 to 2018.
John Maraganore reported 2 open-market purchases and 0 sales here, 2026.
Closing prices and the companies' last annual figures; a − or + is a fact of the close, not a forecast.
